

The BioTech Pharma *Summit*

In-person Agenda



Virtual event: **29NOV-30DEC**
1 month access to BPS Virtual Platform



29 - 30 NOV 2021, Porto, Portugal

Sheraton Porto Hotel & Spa:

R. do Ten. Valadim 146, 4100-476 Porto

Sponsored *by*



Catalent®




SYMPROVE™



NOVATEK
INTERNATIONAL

=





Index



Antibody Engineering | Biomarkers | Biobanking | Liquid Biopsy

Inhalation & Respiratory Drug Delivery

Pharmacovigilance & Drug Safety

Aseptic Processing | Pre-filled Syringes

Gut-Brain Axis | Human & Skin Microbiome

Networking *Events*



November 28

Cocktail Reception 18:00 – 20:00 (Location: Sheraton Hotel, Ground Floor)

November 29

Speed Networking (All meeting rooms): 10:00

Coffee Breaks: 10:30 – 15:30

Lunch Break: 13:00


Gala Dinner: 20:00 – 23:00 (Location: Sheraton Hotel, 1st Floor)

November 30 – Coffee Breaks: 10:30 | 15:00

Antibody Engineering Biomarkers

Biobanking

Liquid Biopsy





Antibody Engineering

The Antibody Engineering & Therapeutics event will provide the latest science, technology and partners to accelerate antibody & protein therapies, ADCs, Bispecifics and Immuno-Oncology. This event will shed light on the progress in discovery, development and therapeutics of novel protein therapeutics, and the latest breakthrough engineering next-generation antibody formats. The conference offers a unique opportunity to reach the pre-eminent researchers working in his important field of science from both the industry and academic sectors.

Biomarkers & Biobanking

The Biomarkers & Biobanking sessions will bring together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, Biobanking and leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the conference a perfect meeting-place to share experience, foster collaborations across industry and academia, evaluate emerging technologies and all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.

Liquid Biopsy

At the Liquid Biopsy sessions we will present some recent developments with regards to exosome and ctDNA research and understand the future perspectives on the areas of research for these biomarkers. We believe these non-invasive capabilities and their potential for diagnostic development can influence treatment selections and aid precision cancer therapies.

Day 1

Antibody Engineering / Biomarkers / Biobanking / Liquid Biopsy

08:00 - 08:50

Registration & Welcome Coffee

08:50 - 09:00

Chairperson Opening Address

ANTIBODY ENGINEERING

Chairperson for the morning sessions:

Marc A. van Dijk, Chief Technology Officer at Agenus Inc.

09:00 - 09:30

Antibody Manufacturing Strategies
during a Pandemic

Nick Hutchinson, Business Steering Group Lead for
Mammalian Cell Culture Services at FUJIFILM Diosynth
Biotechnologies

09:30 - 10:00

Novel Solution For High Throughput Antibody
And Protein Purification Using Magnetic Beads

Nishant Saxena, Ph.D. Product Manager,
Protein Purification at GenScript Inc.

10:00 - 10:30

Speed Networking

10:30 - 11:00

Morning Coffee & Networking Break

11:00 - 11:30

Discovery and engineering
of Immuno-oncology antibodies – Effective
formats and impactful combinations

Marc A. van Dijk, Chief Technology Officer at Agenus Inc.

11:30 - 12:00

Funneling while maintaining diversity:
strategies for therapeutic antibody campaigns

Ilse Roodink, Chief Scientific Officer at ImmunoPrecise
Antibodies

12:00 - 13:00 – Panel Discussion:

Cell Therapy: Promise of the Next Generation

Panelists:

Ilse Roodink; Nishant Saxena; Nick Hutchinson

Moderator: Marc A. van Dijk

13:00 - 14:00

Lunch Break

BIOMARKERS

Chairperson for the afternoon sessions:

Dr. Jörg Engelbergs, Scientific-Regulatory Expert
at Paul-Ehrlich-Institut & European Medicines Agency

14:00 - 14:30

Epigenetic biomarkers for Type 2 Diabetes
from plasma - and saliva derived extracellular
vesicles

Dr. Christa Noehammer, Senior Scientist at AIT (Austrian
Institute of Technology)

14:30 - 15:00

Overcoming the challenges of RNASeq
with extraction-free, low sample input gene
expression profiling by the HTG
Transcriptome Panel

Selina Gaertner, Medical Affairs Manager EMEA at HTG
Molecular Diagnostics

15:00 - 15:30

Regulatory-scientific challenges for predictive
biomarker based personalized medicines

Dr. Jörg Engelbergs, Scientific-Regulatory Expert
at Paul-Ehrlich-Institut & European Medicines Agency

15:30 - 16:00

Afternoon Coffee & Networking Break

16:00 - 16:30

Biomarkers in pathology and radiology

Carla Leibowitz, Chief BD Officer at Paige.AI

16:30-17:30 – Panel Discussion:

Unlocking the potential of precision medicine
in Europe – Barriers to accessing high-quality
biomarker testing

Panelists:

Dr. Christa Noehammer; Selina Gaertner; Carla Leibowitz

Moderator: Dr. Jörg Engelbergs

17:30

End of the sessions

20:00 - 23:00

Gala Dinner – Sheraton Hotel Porto

Notes

Day 2

Antibody Engineering / Biomarkers / Biobanking / Liquid Biopsy

08:00 - 08:20

Registration & Coffee

08:20 - 08:30

Chairperson Opening Address

LIQUID BIOPSY & BIOBANKING

Chairperson for the morning sessions:

Dr. Catherine Alix-Panabières, Director LCCRH
at the University Medical Center of Montpellier

08:30 - 09:00

Current challenges of liquid biopsy research

Klaus Pantel, Chairman of the Institute of Tumour Biology
at the University Medical Center Hamburg-Eppendorf

09:00 - 09:30

Liquid Biopsy: From Discovery to Clinical
Application

Dr. Catherine Alix-Panabières, Director LCCRH
at the University Medical Center of Montpellier

09:30 - 10:00

Modern Biobanking - Critical Success Factors
and future considerations

Karine Sargsyan, Chief Operating Officer at Biobank Graz

10:00 - 10:30

From Biobanking to Personal medicine
and Prevention

Prof. Andres Metspalu, Professor at University of Tartu

10:30 - 11:00

Morning Coffee & Networking Break

ANTIBODY ENGINEERING

Chairperson for the morning sessions:

Heather Schwoebel, Senior Vice President of BD,
Head of Platform Licensing at Allog Therapeutics, Inc.

11:00 - 11:30 – [Live Streaming]

Fully human antibody discovery strategy

Li Chen, Director of Biologics Discovery
at GenScript ProBio

11:30 - 12:00

Single-chain TNFSF ligands as building blocks
for costimulatory bispecifics

Dr. Katharina Billian-Frey, Head of Protein Engineering
at Apogenix AG

12:00 - 13:00 – Panel Discussion:

The challenges with developing therapeutic
monoclonal antibodies for pandemic
application

Panelists:

Oren Beske; Katharina Billian-Frey; Harald Kolmar

Moderator: Dr. Katharina Billian-Frey

13:00 - 14:00

Lunch Break

Chairperson for the afternoon sessions:

Mattias Levin Sr Scientist, Antibody Engineering at
Alligator Bioscience

14:00 - 14:30

Leap In Transposase Platform: From shiny and
new to tried and true

Oren Beske, Ph.D. Amalgamator of Business and Biology
at ATUM

14:30 - 15:00

Bispecific $\gamma\delta$ -T cell engagers for the treatment
of cancer

Paul W.H.I. Parren, PhD, Executive Vice President and
Head of R&D at Lava Therapeutics

15:00 - 15:30

Building a Biotechnology Ecosystem

Heather Schwoebel, Senior Vice President of BD, Head of

Platform Licensing at Alloy Therapeutics, Inc.

15:30 - 16:00

Afternoon Coffee & Networking Break

16:00 - 16:30

The art of making multifunctional antibodies: therapeutic opportunities and technical challenges

Harald Kolmar, Ph.D. Department Head and Professor of Applied Biochemistry at Technical University of Darmstadt

16:30 - 17:00

Neo-X': A bispecific antibody concept targeting CD40 and tumor antigens to enhance neoantigen cross-presentation and T cell priming

Mattias Levin Sr Scientist, Antibody Engineering at Alligator Bioscience

17:30

Chairperson closing remarks
& *End of the sessions*

Notes


Inhalation & Respiratory *Drug Delivery*

The IRDD Stream is designed for senior industry experts that will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses on the regulatory pathways for inhaled therapies and challenges of bringing respiratory products to market. The agenda also features key case studies on the latest trends in inhalation devices, from inhaled ins. to gene therapy.



A recent report from the Pharmaceutical Research and Manufacturers of America (PhRMA) found America's biopharmaceutical companies are developing about 130 new medicines for the millions of patients affected by respiratory diseases: chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, and asthma.

These medicines represent critical advancements in respiratory care and improving quality of life. In addition to the drugs, devices delivering those products are being designed to improve the quality of life for an aging population, children, and those who tend not to comply to dosing regimens because they don't know how to use the device. The global respiratory care devices market is expected to exceed more than \$24 billion by 2022,² and could exceed \$33 billion by 2023.



Day 1

Inhalation & Respiratory Drug Delivery

08:00 - 08:50

Registration & Welcome Coffee

08:50 - 09:00

Chairperson Opening Address

PART I: THE CHALLENGES OF DEVELOPING INHALATION DRUGS

Chairperson for the morning sessions:

Anna Sipitanou, Business Development Manager
at Copley Scientific

09:00 - 09:30 – [Live Streaming]

Biologics Delivered in Liquid Form
by Soft-Mist-Inhalers (SMI)

Bernhard Müllinger, General Manager, Chief Operating
Officer at Resyca

09:30 - 10:00

IVIVC testing for OINDP products
- Bridging the gap and accelerating product
to market journey

Anna Sipitanou, Business Development Manager
at Copley Scientific

10:00 - 10:30

Speed Networking

10:30 - 11:00

Morning Coffee & Networking Break

11:00 - 11:30

Early Phase Clinical Trials for Inhaled Drugs
- Challenges and Opportunities

Aernout van Haarst, PhD Director, Scientific Affairs
at Celerion

11:30 - 12:00

Accurate dosimetry predictions for evolving
liquid aerosol delivery

Arkadiusz Kuczaj, PhD, Manager Aerosol Research and
Dosimetry at Philip Morris International Research and
Development

PART II: INHALATION FORMULATION SOLUTIONS & TECHNOLOGY

12:00 - 12:30

High Dosage DPI – formulation and process
development considerations

Beatriz Noriega Fernandes, Scientist, Formulation Group -
Drug Product Development at Hovione

13:00 - 14:00

Lunch Break

Chairperson for the afternoon sessions:

Markus Mezger, CEO at Mematec solutions

14:00 - 14:30

Formulation Development Challenges and
Pitfalls When Developing Dry Powder Inhalers

Martin Wing-King, Director of Project Management at
Quotient Sciences

14:30 - 15:00

The development and supply of respiratory
medicines

David Wyatt, Chief Operating Officer at Aston Particle
Technologies

15:00 - 15:30

MDPI for 2 API

Markus Mezger, CEO at Mematec solutions

15:30 - 16:00

Afternoon Coffee & Networking Break

16:00 - 16:30

Get it right first time: Inhaler technology and
manufacturing

Marco Laackmann, Director Inhalation Technology
at Harro Höfliger

16:30-17:30 – Panel Discussion:

Artificial Intelligence/Machine Learning in
Dry Powder Inhalers in the Digitalization Era:
Current Status and Future Perspectives

Panelists:

Markus Mezger; David Wyatt

Moderator: Markus Mezger

17:30

End of the sessions

20:00 - 23:00

Gala Dinner – Sheraton Hotel Porto

Notes

Day 2

Inhalation & Respiratory Drug Delivery

08:00 - 08:40

Registration & Coffee

08:50 - 09:00

Chairperson Opening Address

PART III: NEW APPROACHES TO TREATING RESPIRATORY DISEASES

Chairperson for the morning & afternoon sessions:
Nélio Drumond, Senior Principal Scientist at Takeda Pharmaceuticals

09:00 - 09:30

Unmet Needs and Future Trends in Respiratory Drug Delivery

Paul Johnson, Managing Director at Paul Johnson Consulting Limited

09:30 - 10:00

Towards development of patient-centric inhalers: Leveraging human factors, inhalation device and formulation science

Nélio Drumond, Senior Principal Scientist at Takeda Pharmaceuticals

10:00 - 10:30

Are Sustainability, Reusability and Carbon Neutrality Major Trends for Devices in the Future?

Felix Weiland, Head of Product & Process Technology at Boehringer Ingelheim

10:30 - 11:00

Morning Coffee & Networking Break

PART IV: NEW ANALYTICAL INSIGHTS INTO DRY POWDER FORMULATIONS FOR INHALATION

11:00 - 11:30

Digital Pharmaceuticals: A case study

Mark Milton-Edwards, Head of Product & Health Solutions - Digital Health at Teva Pharmaceuticals

11:30 - 12:00 – [Live Streaming]

ARCUS®: Engineered Spray Dried Particles for Inhalation Delivery

Michael Tauber, Senior Director of Pharmaceutical Development and Technical Operations at Acorda Therapeutics

12:00 - 13:00 – Panel Discussion:

Future directions in inhalation and respiratory drug delivery research

Panelists:

Mark Milton-Edwards; Felix Weiland; Paul Johnson

Moderator: Nélio Drumond

13:00 - 14:00

Lunch Break

PART V: NEW APPROACHES TO INHALATION PRODUCT DEVELOPMENT AND PRODUCTION

14:00 - 14:30

Inhalation and Nasal routes as stairways to drug Innovation

Hugo Almeida, International Business Development Consultant at AdAlvo (an Alvogen subsidiary)

14:30 - 15:00 – [Live Streaming]

Science base and challenges of therapeutic equivalence of respiratory products

Jörg Schiewe, Head of Global CMC Experts at Boehringer Ingelheim

15:00 - 15:30 – [Live Streaming]


Musings on High Dose Powder Delivery

Jeffry Weers, Chief Technical Officer at cystetic Medicines, Inc

15:30

Chairperson closing remarks

& End of the sessions




Notes

Pharmacovigilance & Drug Safety

The Pharmacovigilance stream will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug safety, and contribute to the public health. It will also allow all its participants to interact with the experts, discuss the various developments, challenges faced and innovations in the field.



With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in the recent years, which is apparent with the excess documentation of adversities and drug toxicities. In this context, the drug safety and pharmacovigilance has emerged as a dynamic clinical and scientific discipline to provide adequate information and ensure health safety by the joint interaction of doctors and patients in choosing appropriate treatment method and drug.



Day 1

Pharmacovigilance & Drug Safety

08:00 - 08:50

Registration & Welcome Coffee

08:50 - 09:00

Chairperson Opening Address

Chairperson for the morning & afternoon sessions:

Budhesh Dhamija, Senior Manager, Regulatory Intelligence and Policy – Europe at CSL Behring

09:00 - 09:30

Synergies between Regulatory Affairs and Pharmacovigilance

Budhesh Dhamija, Senior Manager, Regulatory Intelligence and Policy – Europe at CSL Behring

09:30 - 10:00

How to define PV strategy and build an effective Regulatory Intelligence function

Julia Appelskog, Pharmacovigilance Director, EU QPPV, Head of QPPVs & Safety Consulting Services at TFS

10:00 - 10:30

Speed Networking

10:30 - 11:00

Morning Coffee & Networking Break

11:00 - 11:30

Adoption of Artificial Intelligence in Pharmacovigilance: a framework for the development of cognitive services and the role of the Drug Safety Professional

Salvatore Cicirello, Head of Safety Science & PASS, Global Drug Safety & Risk Management at Bristol Myers Squibb

11:30 - 12:00

EudraVigilance, XEVMPD, EVDAS, SPOR, EMA unique account news

Calin Lungu, CEO at DDCS S.A.

12:00-13:00 – Panel Discussion:

PV Outsourcing: Challenges and Opportunities

Panelists:

Calin Lungu; Salvatore Cicirello; Julia Appelskog

Moderator: Budhesh Dhamija

13:00 - 14:00

Lunch Break

14:00 - 14:30 – [On-demand]

PSMF in a global environment: compliance with local requirements

Margherita D'Antuono, Corporate Pharmacovigilance Director - EU QPPV at Italfarmaco Group

14:30 - 15:00 – [On-demand]

Cardiovascular safety issues during phase III-IV for non-cardiovascular trials


Anupam Agarwal, Vice President, Global Head of Drug Safety and Pharmacovigilance at Zogenix, Inc.

15:00

End of the sessions

20:00 - 23:00

Gala Dinner – Sheraton Hotel Porto



Notes

Notes section containing several horizontal lines for writing.

Day 2

Inhalation & Respiratory Drug Delivery

08:00 - 08:40

Registration & Coffee

08:50 - 09:00

Chairperson Opening Address

Chairperson for the morning & afternoon sessions:

Uwe Gudat, Head of Medical Affairs & CSPV at Fresenius Kabi at Fresenius Kabi SwissBioSim GmbH

09:00 - 09:30

Communicating safety safely:

what can we learn from Covid-19?

Uwe Gudat, Head of Medical Affairs & CSPV at Fresenius Kabi at Fresenius Kabi SwissBioSim GmbH

09:30 - 10:00

New Trends in Signal Detection and Management

Robert Weber, Product Management Director at Oracle

10:00 - 10:30 – [Live Streaming]

Structured and Quantitative Benefit-Risk evaluation for medicinal products: how can it make a difference?

Marie-Laure Kürzinger, Benefit-Risk Expert - Global Epidemiology & Benefit-Risk Evaluation - Global Pharmacovigilance at Sanofi

10:30 - 11:00

Morning Coffee & Networking Break

11:00 - 11:30

The Evolution of the Safety Scientist

Dennis Vargo, Vice President and Head of Drug Safety and Pharmacovigilance at Akebia

11:30 - 12:00

PV challenges during pandemic

Mircea Ciuca, Global Therapeutic Area Head - Global Clinical Safety and Pharmacovigilance at CSL Behring

12:00 - 13:00 – Panel Discussion:

Impact of Covid-19 Pandemic on PV Activities


Panelists:

Mircea Ciuca; Dennis Vargo; Robert Weber


Moderator: Uwe Gudat

13:00 - 14:00

End of the sessions & Lunch Break





Notes



Aseptic Processing */ Pre-filled Syringes*

Aseptic Processing

Aseptic Processing Technology event will overview regulatory updates and their implementation, main challenges and overcome consideration, new technologies and innovations to avoid mistakes and ensure safe highly potent aseptic production for both sides - manufacturer and patient.



Pre-filled Syringes

The Pre-Filled Syringes conference will bring together all specialists in medical devices and pharmaceuticals to share experience about new technology trends, design considerations, technical developments of quality and materials in pre-filled syringes.

Day 1

Aseptic Processing | Pre-filled Syringes

08:00 - 08:50

Registration & Welcome Coffee

08:50 - 09:00

Chairperson Opening Address

PRE-FILLED SYRINGES

Chairperson for the morning sessions:

Richard Denk, Senior Consultant Aseptic Processing
& Containment at SKAN AG

09:00 - 09:30

Extractable metals: potential sources in your
Prefilled Syringes, risk management and
change control

Beate Treffler, Market Development Manager Healthcare
EMEA at Avient Corporation

09:30 - 10:00

Impact of the EU MDR 2017/745

Bassil Akra, CEO at AKRA TEAM GmbH

10:00 - 10:30

Speed Networking

10:30 - 11:00

Morning Coffee & Networking Break

11:00 - 11:30 – [Live Streaming]

User-driven product development:
Focus on self-injection devices

Jakob Lange, Account Director at Ypsomed AG

ASEPTIC PROCESSING

11:30 - 12:00

Contamination and Cross Contamination
Control during Aseptic Manufacturing

Richard Denk, Senior Consultant Aseptic Processing
& Containment at SKAN AG

12:00 - 12:45 – Panel Discussion:

Technical and regulatory trends in Aseptic Fill
& Finish of Pre-filled Syringes

Panelists:

Andreas Kerschbaumer; Bassil Akra; Beate Treffler

Moderator: Richard Denk

13:00 - 14:00

Lunch Break

Chairperson for the afternoon sessions:

Dr. Thomas Becker, Director Site Quality at Recipharm

14:00 - 14:30

Innovative and Agile Approaches in the
Aseptic Manufacturing of Lyophilised Vial
Drug Products

Dr. Thomas Becker, Director Site Quality at Recipharm

14:30 - 15:00

Aseptic Filling System for Combination
Products (Ready-to-Mix)

Pietro Bosi, Sales Manager Pharma Div. at Comecer

15:00 - 15:30

Learn How to Trend & Analyze Environmental
Monitoring Data

Susan Cleary, Director of Product Development
at Novatek International

15:30 - 16:00

Afternoon Coffee & Networking Break

16:00 - 16:30

Concept and Implementation of a Global
Contamination Control Strategy

Christoph Hansy, Global Microbiology Management
at Takeda

16:30-17:30 – Panel Discussion:

Aseptic Manufacturing Process in times
of COVID-19

Panelists:

Christoph Hansy; Susan Cleary; Pietro Bosi

Moderator: Dr. Thomas Becker

17:30

End of the sessions

20:00 - 23:00

Gala Dinner – Sheraton Hotel Porto

Notes

Day 2

Aseptic Processing | Pre-filled Syringes

08:00 - 08:50

Registration & Welcome Coffee

08:50 - 09:00

Chairperson Opening Address

PRE-FILLED SYRINGES

Chairperson for the morning sessions:

Raphael Nudelman, Senior Director Impurity Expert, R&D Operations at Teva Pharmaceuticals

09:00 - 09:30

Extractables & Leachables Qualification
in Pre-Filled Syringes

Raphael Nudelman, Senior Director Impurity Expert, R&D Operations at Teva Pharmaceuticals

09:30 - 10:00 – [Live Streaming]

Nonclinical safety evaluation of extractables
and leachables when developing a pre-filled
syringe drug device combination product

Clemens Günther, Director Senior Expert Nonclinical Safety at Bayer AG

10:00 - 10:30

Modular Feeding Systems for Parenterals, such
as Pre-filled Syringes and Injection Devices

Ashley Reynolds, Pharma Technology Sales and Marketing
at Körber Group company

10:30 - 11:00

Morning Coffee & Networking Break

11:00 - 11:30

Aseptic Production and IPC

Andreas Kerschbaumer, Senior Technical Manager
at Sandoz GmbH

11:30 - 12:00 – [Live Streaming]

An industrial perspective for fill & finish
of nested syringes

Franz Kainz, PhD Vice President, Global Contract
Manufacturing at Fresenius Kabi Deutschland GmbH

12:00 - 12:30 – [Live Streaming]

Beyond glass – benefits for biological drugs
of a new hybrid material for primary
packaging container

Holger Krenz, Vice President Applications Development
Europe at SiO2 Material Science

ASEPTIC PROCESSING

12:30 - 13:00

Continuous Processing opening new
possibilities

Harald Stahl, Senior Director Innovation and Strategy
at GEA AG

13:00 - 14:00

Lunch Break

Chairperson for the afternoon sessions:

Keith W. Dodson, Vice President of Business Development
at AST (Automated Systems of Tacoma)

14:00 - 14:30

Aseptic bag processing: bridging the gap

Christian Kolleck, Business Unit Leader Pharma Liquid /
Aseptic at Harro Höfliger

14:30 - 15:00

Use of Robotics in Flexible Format Aseptic
Filling

Keith W. Dodson, Vice President of Business Development
at AST (Automated Systems of Tacoma)


15:00 - 15:30 – [Live Streaming]

Contamination Control Strategy, an
Implementation approach

Walid El Azab, Senior Manager Technical Service at STERIS

15:30 - 16:00

Chairperson closing remarks
& Networking Coffee



Notes



Gut-Brain Axis

The Gut-Brain Axis will be dedicated to help large pharma, biotech, academics and clinicians exploring and understand the Human Microbiome Market, GBA in demonstrating disease causation. Over the last decade, the microbiome has become one of the trendiest areas of biology, and the research has made clear that the microbiome is fundamental to overall health.

Probiotics, Human & Skin Microbiome

The Probiotics, Human & Skin Microbiome event, brings together leading scientists, physicians, and senior leaders to explore the potential insights into the Probiotics, Human & Skin Microbiome that exhibits significant potential in the near future. The event will showcase Industry Case Studies and regulatory insights of the skin microbiome and its impact on cutaneous structure in healthy, aged and compromised state as well as integrated approaches that has been used in human gut microbiome research.



Gut-Brain Axis/ *Probiotics, Human & Skin Microbiome*



Day 1

Gut-Brain Axis / Probiotics, Human & Skin Microbiome

08:00 - 08:50

Registration & Welcome Coffee

08:50 - 09:00

Chairperson Opening Address

GUT-BRAIN AXIS

Chairperson for the morning sessions:

Shahram Lavasani, Founder and CEO at ImmuneBiotech AB

09:00 - 09:30

ImmuneBiotics for management of neurological conditions – new clinical evidence

Shahram Lavasani, Founder and CEO at ImmuneBiotech AB

09:30 - 10:00

The gut-brain and brain-gut axes in human disease

Wouter de Jonge Professor of Neurogastroenterology at AMC, CoFounder of Gut Research

10:00 - 10:30

Speed Networking

10:30 - 11:00

Morning Coffee & Networking Break

11:00 - 11:30

Leveraging the microbiome in Alzheimer's disease progression and neuroinflammation

Alessio Mylonas, Research Scientist at AC Immune

11:30 - 12:00

Novel Microbiome Approach For Management of Alzheimer Diseases

Satya Prakash, Professor of Biomedical Engineering, Artificial Cells and Organs, Physiology, Experimental Medicine and Surgery in the Faculty of Medicine at McGill University

12:00 - 12:30 – Panel Discussion:

Pioneering precision probiotics: from molecular mimetism to product commercialization

Nina Vinot, International Sales Director at TargEDys

12:30 - 13:00 – Panel Discussion:

Clinical Trials in the Gut-Brain Axis: Challenges & Opportunities

Panelists:

Satya Prakash; Alessio Mylonas; Nina Vinot

Moderator: Shahram Lavasani

13:00 - 14:00

Lunch Break

SKIN MICROBIOME

Chairperson for the afternoon sessions:

George Paraskevagos, Executive Director at International Probiotics Association (IPA)

14:00 - 14:30

The underarm microbiome and the development of new probiotics

Dr Chris Callewaert, Senior Post-doctoral Researcher at Ghent University, Belgium

14:30 - 15:00

Microbes and the Skin: Science, Regulation and the Marketplace

George Paraskevagos, Executive Director at International Probiotics Association (IPA)

15:00 - 15:30

S-Biomedic approach of direct skin microbiome modulation

Susan Cleary, Director of Product Development
Amine Zorgani, Head of Microbiology R&D at S-Biomedic

15:30 - 16:00

Afternoon Coffee & Networking Break

16:00 - 16:30

Topical rosemary extract containing carnosic acid inhibits *Staphylococcus aureus* virulence in vitro and reduces the signs and symptoms of adult skin irritation and eczema in a randomized, double-blind, vehicle-controlled pilot study

Greg Hillebrand, Senior Principal Research Scientist for Amway

16:30 - 17:00

Scalp Microbiome, how to develop specific products, and for what results?

Marie Drago, PharmD, Founder - Gallinée

17:00 - 17:30

Ammonia Oxidizing Bacteria as a Treatment for Inflammatory Skin Disease

Daniel Brownell, Director, Research & Development, AOBiome Therapeutics

17:30 - 18:00 – Panel Discussion:

The Development Of New Therapies In Skin Microbiome

Panelists: Daniel Brownell; Dr Chris Callewaert; Marie Drago, Greg Hillebrand

Moderator: George Paraskevakos

18:30

End of the sessions

20:00 - 23:00

Gala Dinner – Sheraton Hotel Porto

Day 2

Gut-Brain Axis / Probiotics, Human & Skin Microbiome

08:00 - 08:20

Registration & Welcome Coffee

08:20 - 08:30

Chairperson Opening Address

GUT-BRAIN AXIS

Chairperson for the morning sessions:

Richard Denk, Senior Consultant Aseptic Processing
Lionel Breton, Cofounder and executive VP of IDEC
therapeutics

09:00 - 09:30

Extractable metals: potential sources in your
Prefilled Syringes, risk management and
change control

Beate Treffler, Market Development Manager Healthcare
EMEA at Avient Corporation

08:30 - 09:00

Mechanisms and current evidence of prebiot-
ics in gut-brain-axis

Dr. Yoghatama Zanger, Manager Nutrition Science
at BENE0, Germany

09:00 - 09:30 – [On-demand]

Molecular Mimicry of microbial and dietary
immune triggers as the key to disease
complexity in Parkinson

Martha Carlin, Chief Executive Officer at The BioCollective

09:30 - 10:00 – [Live Streaming]

Diet & the Gut-Brain Axis: from concept
to product

Marcus Böhme, R&D Specialist at Nestlé Research

10:00 - 10:30

Can a diet tackle stress?

Nadejda Lupolova, Health Coach

10:30 - 11:00

Morning Coffee & Networking Break

HUMAN MICROBIOME

11:00 - 11:30

Considering the Microbiome Interorgans Axis
(MIA) as a future option in Health & Diseases

Lionel Breton, Cofounder and executive VP of IDEC
therapeutics

11:30 - 12:00

The human microbiome is not an island

Richard Denk, Senior Consultant Aseptic Processing
Newton Gomes Researcher University of
Aveiro/Co-founder at InnerCore Microbiome

12:00 - 12:45 – Panel Discussion:

Pre and Probiotics: A Shift from
Pharmaceuticals to Nutraceuticals Directions
for Research

Panelists:

Lionel Breton; Nina Vinot; Dr. Yoghatama Zanger

Moderator: Marcus Claesson

13:00 - 14:00

Lunch Break

PROBIOTICS & HUMAN MICROBIOME

Chairperson for the afternoon sessions:

Marcus Claesson, Chief Executive Officer at SeqBiome

14:00 - 14:30

Developing global standards for the
microbiome field

Chrysi Sergaki, Microbiome Scientist at National Institute
for Biological Standards and Control (NIBSC/MHRA)

14:30 - 15:00

Unravelling the microbiome of inflammatory
bowel disease

Marcus Claesson, Chief Executive Officer at SeqBiome

15:00 - 15:30

Measuring the microbiome: Path towards products that work in balance with the microbiome

Dr. Eline Klaassens, Product Manager Human Health at BaseClear B.V.

15:30 - 16:00

Afternoon Coffee & Networking Break

16:00 - 16:30

Fertibiome, a probiotic for couples with infertility problems

Sergio Esteban, Project Manager at Probisearch SLU

16:30

Chairperson closing remarks

& End of the sessions

Notes

Premium *sponsors*



GenScript Biotech

GenScript is a world leader in biotechnology reagent services, providing life sciences services and products to over 200,000 scientists in over 100 countries worldwide. Established in 2002 in New Jersey, United States, the company was one of the first to commercialize gene synthesis as well as establish fully integrated capabilities for custom peptide synthesis, complex protein expression and engineering, custom antibody development and engineering, in vitro/in vivo pharmacology, as well as a variety of other research-focused catalogue products.



Biose Industrie

Biose Industrie is a Contract Development and Manufacturing Organization (CDMO), specialised in Live Biotherapeutic Products. Founded in 1951, Biose Industrie has more than 65 years of experience in the development and production of live bacteria based drugs. Company offers lab development specialised in microbiology (anaerobic, aerobic, GMO strains) and is Drug GMP certified for the manufacturing of API (From 300L to 3 500L), clinical batches and commercial drug products (capsules in blisters or pills, sachets).

The worlds leading CDMO for Live Biotherapeutics
Developing and producing Bacteria as a drug for over 70 years



One single partner

Currently managing over 25 clinical lines from Phase I to Phase III

Main facility, R&D and GMP production - **Aurillac France** R&D and Pilot Plant - **Boston USA** / www.biose.com
Contact : Richard Ellis Head of Business Development + 33 6 40 97 03 20 - r.ellis@biose.com



Customized Services To Accelerate Your Research



860 Centennial Ave., Piscataway, NJ 08854, USA | GenScript Europe Headquarter, BioPartner Building 4, Robert Boyleweg 4, 2333 CG, Leiden, Netherlands | Phone: 31-071-569-0120 | Fax: +31 (0)65 954 406 | Email: support.EU@genscript.com

Catalent®

End-to-end
inhalation
expertise
across dose
forms.

DEVELOPMENT

DPI, MDI & NASAL

CLINICAL TO
COMMERCIAL SCALE



End-to-end inhalation solutions.
Advanced technologies.
Better treatments.

US +1 888 SOLUTION (765-8846)
EUR 00800 8855 6178
catalent.com/inhalation


© 2021 Catalent, Inc. All rights reserved.

Catalent®

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years' industry experience, Catalent has proven expertise in bringing more customers' products to market faster, enhancing product performance, and ensuring reliable clinical and commercial product supply.



Notes



Handwriting practice lines consisting of eight horizontal lines. The first four lines are light gray, and the last four lines are light blue. The lines are evenly spaced and extend across the width of the page.



www.biotechpharmasummit.com